Genmab — April 2014
-
jo men genmabs potentiale er enormt. Ligemeget om kursen falder til 150. bare hold fast så skal man nok få gevinsten
-
jvf business.dk i dag kommer der ikke en opjustering af FYE fra GEN på baggrund af godkendelsen.
-
det ser også ud til at Medwatch skriver en hel del i dag
-
Ja - den take up som inv89 postede på Gazyva, var ikke imponerende. Var det chf 8 mio Roche havde omsat for i Q1? Nu skal behandlingerne lige løbes igang og onkologerne vil nok også lige se deres egne erfaringer an, inden de springer på - men det er ikke en imponerende omsætning
-
Page or document not found | European Medicines Agency (EMA)
We are sorry, but the content you tried to access is unavailable at the link you used, which was either incorrect or out-of-date. To help you find what you are looking for, we have included some useful tips.
European Medicines Agency (EMA) (www.ema.europa.eu)
-
http://www.nature.com/nbt/journal/v28/n2/pdf/nbt0210-105.pdf forhåbentlig ikke sådan at de dækker over rtx (er der en der har adgang)
-
-
-
EU har undersøgt 19 stoffer (se listen til højre på linket): http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001641.jsp&mid=WC0b01ac058004d5c1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind